Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy
Mechanism study published in Blood (2011)
Abstract
Whereas it is generally perceived to be harmful, enhanced coagulation activation can also convey salutary effects. The high prevalence of the prothrombotic factor V Leiden (FVL) mutation in whites has been attributed to a positive selection pressure (eg, resulting from reduced blood loss or improved survival in sepsis). The consequences of enhanced coagulation activation, as observed in FVL carriers, on microvascular diabetic complications remain unknown. We therefore investigated the role of FVL in diabetic nephropathy. In heterozygous or homozygous diabetic FVL mice, albuminuria and indices of diabetic nephropathy were reduced compared with diabetic wild-type mice. This was associated with reduced glomerular apoptosis and preservation of podocytes in diabetic FVL-positive mice. In vitro, low-dose thrombin (50pM) prevented, whereas high-dose thrombin (20nM) aggravated, glucose-induced apoptosis in podocytes. In diabetic patients, the FVL mutation, but not the plasminogen activator inhibitor-1 4G/5G polymorphism, is associated with reduced albuminuria, which is consistent with a nephroprotective role of low but sustained thrombin generation. Consistently, anticoagulation of diabetic FVL-positive mice with hirudin abolished the nephroprotective effect. These results identify a nephroprotective function of low but sustained thrombin levels in FVL carriers, supporting a dual, context-dependent function of thrombin in chronic diseases.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Low-grade sustained coagulation activation via Factor V Leiden ameliorates glucose-induced podocyte apoptosis — supports hirudin therapeutic-window concept in DKD.
Por qué esto importa para la hirudoterapia
Este estudio investigó cómo el factor V Leiden (FVL), una mutación protrombótica, afecta a la nefropatía diabética, hallando que niveles bajos de activación de la coagulación pueden proteger los podocitos y reducir la albuminuria en ratones. Notablemente, cuando los ratones diabéticos con FVL fueron tratados con el anticoagulante de la sanguijuela hirudina, este efecto nefroprotector se abolió. Este hallazgo es altamente relevante para la Sociedad Americana de Hirudoterapia, ya que destaca una interacción dependiente del contexto donde los anticoagulantes derivados de la sanguijuela pueden contrarrestar las vías protectoras de la trombina en estados patológicos específicos. La limitación es que estos hallazgos derivan principalmente de modelos animales y experimentos in vitro, y no reflejan las aplicaciones terapéuticas típicas de la hirudina.
Citación
Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy.
Wang H et al. · Blood, 2011
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026